Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sophie Whyte

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2011
Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United KingdomSophie Whyte, Katy L Cooper, Matt D Stevenson, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|April 24, 2016
How to Invest in Getting Cost-effective Technologies into Practice? A Framework for Value of Implementation Analysis Applied to Novel Oral AnticoagulantsRita Faria, Simon Walker, Sophie Whyte, et al.
BMC Cancer|September 28, 2011
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysisKaty L Cooper, Jason Madan, Sophie Whyte, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2016
Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?Sophie Whyte, Simon Dixon, Rita Faria, et al.
Pharmacoeconomics|December 13, 2016
Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalLesley Uttley, Sophie Whyte, Timothy Gomersall, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 15, 2011
Consistency between direct and indirect trial evidence: is direct evidence always more reliable?Jason Madan, Matt D Stevenson, Katy L Cooper, et al.
Cancer Management and Research|April 10, 2018
The association between long-term conditions and uptake of population-based screening for colorectal cancer: results from two English cohort studiesBenjamin Kearns, Jim Chilcott, Clare Relton, et al.
Cancer Reports (Hoboken, N.J.)|February 3, 2021
Should colorectal cancer screening start at different ages for men and women? Cost-effectiveness analysis for a resource-constrained serviceChloe Thomas, Olena Mandrik, Sophie Whyte, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|December 17, 2015
Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of LifeDonna Rowen, John Brazier, Clara Mukuria, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 27, 2021
The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic AnalysisChloe Thomas, Olena Mandrik, Catherine L Saunders, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2011
Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United KingdomSophie Whyte, Katy L Cooper, Matt D Stevenson, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|April 24, 2016
How to Invest in Getting Cost-effective Technologies into Practice? A Framework for Value of Implementation Analysis Applied to Novel Oral AnticoagulantsRita Faria, Simon Walker, Sophie Whyte, et al.
BMC Cancer|September 28, 2011
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysisKaty L Cooper, Jason Madan, Sophie Whyte, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2016
Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?Sophie Whyte, Simon Dixon, Rita Faria, et al.
Pharmacoeconomics|December 13, 2016
Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalLesley Uttley, Sophie Whyte, Timothy Gomersall, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 15, 2011
Consistency between direct and indirect trial evidence: is direct evidence always more reliable?Jason Madan, Matt D Stevenson, Katy L Cooper, et al.
Cancer Management and Research|April 10, 2018
The association between long-term conditions and uptake of population-based screening for colorectal cancer: results from two English cohort studiesBenjamin Kearns, Jim Chilcott, Clare Relton, et al.
Cancer Reports (Hoboken, N.J.)|February 3, 2021
Should colorectal cancer screening start at different ages for men and women? Cost-effectiveness analysis for a resource-constrained serviceChloe Thomas, Olena Mandrik, Sophie Whyte, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|December 17, 2015
Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of LifeDonna Rowen, John Brazier, Clara Mukuria, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 27, 2021
The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic AnalysisChloe Thomas, Olena Mandrik, Catherine L Saunders, et al.
Pageof 4